MRC & Asthma UK Centre in Allergic Mechanisms of Asthma

Contact Details

Leukocyte Biology Section, Room 374, Sir Alexander Fleming Building

South Kensington Campus,

Imperial College London

London SW7 2AZ

Telephone

020 7594 3174

Email

a.b.kay@imperial.ac.uk

Profile

Kay and Larche’s work provided the foundation for Circassia’s range of allergy T-cell vaccines based on its proprietary ToleroMune® technology. This technology utilizes allergen epitopes to generate regulatory T cells that suppress allergic immune responses. Clinical results with Circassia’s cat allergy T-cell vaccine show that short treatment regimens can reduce patients’ symptoms while proving well tolerated. In December 2009 – Circassia completed a £15 million fundraising to continue developing the vaccine(s). The investment round, which was led by Imperial Innovations and supported by existing shareholders including Invesco Perpetual and Lansdowne Partners, was oversubscribed and is the company’s third successful fundraising.

MRC & Asthma UK Centre in Allergic Mechanisms of Asthma

Last modified: 04 December 2009 11:38